TY - JOUR
T1 - Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention
AU - Wouthuyzen-Bakker, Marjan
AU - Sebillotte, Marine
AU - ESCMID Study Group for Implant-Associated Infections (ESGIAI)
AU - Lomas, Jose
AU - Taylor, Adrian
AU - Palomares, Eva Benavent
AU - Murillo, Oscar
AU - Parvizi, Javad
AU - Shohat, Noam
AU - Reinoso, Javier Cobo
AU - Sánchez, Rosa Escudero
AU - Fernandez-Sampedro, Marta
AU - Senneville, Eric
AU - Huotari, Kaisa
AU - Barbero, José Maria
AU - Garcia-Cañete, Joaquín
AU - Lora-Tamayo, Jaime
AU - Ferrari, Matteo Carlo
AU - Vaznaisiene, Danguole
AU - Yusuf, Erlangga
AU - Aboltins, Craig
AU - Trebse, Rihard
AU - Salles, Mauro José
AU - Benito, Natividad
AU - Vila, Andrea
AU - Toro, Maria Dolores Del
AU - Kramer, Tobias Siegfried
AU - Petersdorf, Sabine
AU - Diaz-Brito, Vicens
AU - Tufan, Zeliha Kocak
AU - Sanchez, Marisa
AU - Arvieux, Cédric
AU - Soriano, Alex
N1 - Publisher Copyright:
© 2018 The British Infection Association
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Objectives: Debridement, antibiotics and implant retention (DAIR) is the recommended treatment for all acute prosthetic joint infections (PJI), but its efficacy in patients with late acute (LA) PJI is not well described. Methods: Patients diagnosed with LA PJI between 2005 and 2015 were retrospectively evaluated. LA PJI was defined as the development of acute symptoms (≤ 3 weeks) occurring ≥ 3 months after arthroplasty. Failure was defined as: (i) the need for implant removal, (ii) infection related death, (iii) the need for suppressive antibiotic therapy and/or (iv) relapse or reinfection during follow-up. Results: 340 patients from 27 centers were included. The overall failure rate was 45.0% (153/340). Failure was dominated by Staphylococcus aureus PJI (54.7%, 76/139). Significant independent preoperative risk factors for failure according to the multivariate analysis were: fracture as indication for the prosthesis (odds ratio (OR) 5.4), rheumatoid arthritis (OR 5.1), age above 80 years (OR 2.6), male gender (OR 2.0) and C-reactive protein > 150 mg/L (OR 2.0). Exchanging the mobile components during DAIR was the strongest predictor for treatment success (OR 0.35). Conclusion: LA PJIs have a high failure rate. Treatment strategies should be individualized according to patients’ age, comorbidity, clinical presentation and microorganism causing the infection.
AB - Objectives: Debridement, antibiotics and implant retention (DAIR) is the recommended treatment for all acute prosthetic joint infections (PJI), but its efficacy in patients with late acute (LA) PJI is not well described. Methods: Patients diagnosed with LA PJI between 2005 and 2015 were retrospectively evaluated. LA PJI was defined as the development of acute symptoms (≤ 3 weeks) occurring ≥ 3 months after arthroplasty. Failure was defined as: (i) the need for implant removal, (ii) infection related death, (iii) the need for suppressive antibiotic therapy and/or (iv) relapse or reinfection during follow-up. Results: 340 patients from 27 centers were included. The overall failure rate was 45.0% (153/340). Failure was dominated by Staphylococcus aureus PJI (54.7%, 76/139). Significant independent preoperative risk factors for failure according to the multivariate analysis were: fracture as indication for the prosthesis (odds ratio (OR) 5.4), rheumatoid arthritis (OR 5.1), age above 80 years (OR 2.6), male gender (OR 2.0) and C-reactive protein > 150 mg/L (OR 2.0). Exchanging the mobile components during DAIR was the strongest predictor for treatment success (OR 0.35). Conclusion: LA PJIs have a high failure rate. Treatment strategies should be individualized according to patients’ age, comorbidity, clinical presentation and microorganism causing the infection.
UR - http://www.scopus.com/inward/record.url?scp=85054180307&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2018.07.014
DO - 10.1016/j.jinf.2018.07.014
M3 - Article
C2 - 30092305
AN - SCOPUS:85054180307
SN - 0163-4453
VL - 78
SP - 40
EP - 47
JO - Journal of Infection
JF - Journal of Infection
IS - 1
ER -